1.    Huang JF, Huang CF, Yeh ML, Dai CY, Yu ML, Chuang WL*. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? Expert Rev Anti Infect Ther. 2018 Dec;16(12):907-912.

2.    Chen VL, Yeh ML, Le AK, Jun M, Saeed WK, Yang JD, Huang CF, Lee HY, Tsai PC, Lee MH, Giama N, Kim NG, Nguyen PP, Dang H, Ali HA, Zhang N, Huang JF, Dai CY, Chuang WL, Roberts LR, Jun DW, Lim YS, Yu ML*, Nguyen MH*. 2018. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther. 2018 Jul;48(1):44-54.

3.    Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Chou TC, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML*. Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. Clin Transl Gastroenterol. 2018 Jul 2;9(6):166.

4.    Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH*. 2018. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018 May;38(5):895-902.

5.    Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ*, Yu ML*. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep. 2018 Oct 10;8(1):15058.

6.    Huang CF, Wang SC, Chang WT, Yeh ML, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Chen YL, Yu ML*. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Sci Rep. 2018 Oct 25;8(1):15821.

7.    Batsaikhan B, Huang CI, Yeh ML, Huang CF, Liang PC, Hsieh MY, Huang JF, Yu ML, Chuang WL, Lee JC, Lee PL, Dai CY*. 2018. Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018 Nov;33(11):1897-1903.

8.    Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML*. 2018. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. J Gastroenterol Hepatol. 2018 May;33(5):1108-1114.

9.   Huang CF, Wang SC, Yeh ML, Huang CI, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Chen A, Yu ML*.2018. Association of serial serum MHC class I chain-related A measurements with HCC in chronic hepatitis C patients after viral eradication. J Gastroenterol Hepatol. 2018 in press.

10.   Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML*. 2017. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc. 2018 Jan;117(1):54-62.

11.  Yu ML, Chen YL, Huang CF, Lin KH, Yeh ML, Huang CI, Hsieh MH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL*. 2018. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. J Formos Med Assoc. 2018 Jun;117(6):518-526.

12.   Hsieh MH, Yeh ML, Su TH, Liu TW, Huang CF, Huang CI, Wang SC, Huang JF, Dai CY, Kao JH, Chuang WL, Chen PJ, Liu CJ*, Yu ML*. 2017. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. J Formos Med Assoc. 2018 Jun;117(6):497-504.

13.   Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS*, Yu ML*. 2017. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc, 2018 Jan;117(1):14-23.

14.   Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY*, Yu ML*. 2018. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (Baltimore). 2018 Mar;97(10):e9782.

15.  Tsai PC, Liu TW, Huang CF, Yeh ML, Dai CY, Chuang WL, Huang JF, Yu ML*.2018. A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders. J Chin Med Assoc. 2018 Aug;81(8):670-675.

16.  Dai CY, Lin CY, Tsai PC, Lin PY, Yeh ML, Huang CF, Chang WT, Huang JF, Yu ML, Chen YL*. Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. J Chin Med Assoc. 2018 Feb;81(2):155-163.

17.  Yeh ML, Huang CI, Huang CF, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Kuo HT*, Dai CY*, Yu ML, Chuang WL. 2018. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. Oncotarget .2018 Jan; 9(15): 12240-12249.

18.   Dai CY, Tsai YS, Chou WW, Liu T, Huang CF, Wang SC, Tsai PC, Yeh ML, Hsieh MY, Huang CI, Vanson Liu SY, Huang JF, Chuang WL, Yu ML*. 2018. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. Oncotarget. 2018 Jan 10;9(13):11291-11302.

19.   Batsaikhan B, Huang CI, Yeh ML, Huang CF, Hou NJ, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL, Lee JC, Dai CY*. 2018. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget. 2018 Apr 20;9(30):21313-21321.

20.   Yen CH, Hsiao HH. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. Int J Mol Sci. 2018 Nov 7;19(11).

21.   Tsai YF, Huang WC, Cho SF, Hsiao HH, Liu YC, Lin SF, Liu TC, Chang CS Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Medicine (Baltimore). 2018 Jun;97(26):e11322

22.   Tseeleesuren D, Kant R, Yen CH, Hsiao HH, Chen YA. 1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression. Front Pharmacol. 2018 Feb 2;9:65.

23.  Hsu YT, Tsai HJ, Chang JS, Li SS, Tang JL, Yeh SP, Hwang WL, Liu JH, Tan TD, Wang PN, Hsiao HH, Chen TY. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant. 2018 Feb 12.

24.  Cho SF, Wu WH, Yang YH, Liu YC, Hsiao HH, Chang CS. Investigation of treatment pattern, medical resource utilization and demographic prognostic factors in older patients with non-Hodgkin lymphoma: A nationwide population-based study. J Geriatr Oncol. 2018 Jul;9(4):315-320

25.   Huang C.F., Wang S.C., Yeh M.L., Huang C.I., Tsai P.C., Lin Z.Y., Chen S.C., Dai C.Y., Huang J.F., Chuang W.L., Chen A., Yu M.L., Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1111/jgh.14359.

26.   Lin K.H., Huang M.Y., Cheng W.C., Wang S.C., Fang S.H., Tu H.P., Su C.C., Hung Y.L., Liu P.L., Chen C.S., Wang Y.T., Li C.Y., RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment. Sci Rep. 2018 Feb 8;8(1):2672.

Go to top